Back to top
more

DexCom (DXCM)

(Delayed Data from NSDQ)

$115.23 USD

115.23
4,058,090

-3.54 (-2.98%)

Updated Jun 3, 2024 04:00 PM ET

After-Market: $115.11 -0.12 (-0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (147 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for DXCM

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

DexCom, Inc. [DXCM]

Reports for Purchase

Showing records 321 - 340 ( 412 total )

Company: DexCom, Inc.

Industry: Medical - Instruments

Record: 321

02/28/2013

Company Report

Pages: 9

Price: 24.95

Company: DexCom, Inc.

Industry: Medical - Instruments

Record: 322

02/25/2013

Company Report

Pages: 9

Q4 results ahead of expectations, G4 Platinum well received

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: DexCom, Inc.

Industry: Medical - Instruments

Record: 323

02/22/2013

Company Report

Pages: 7

Reports Solid Q4 Financials and Strong G4 Platinum Interest Continues Into 2013

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 25.00

Research Provided by a Third Party

Company: DexCom, Inc.

Industry: Medical - Instruments

Record: 324

02/21/2013

Company Report

Pages: 7

Historical survey of 698 CGM users

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: DexCom, Inc.

Industry: Medical - Instruments

Record: 325

01/08/2013

Company Report

Pages: 7

Preannounced Q4 Product Revenue Above Consensus and Issued In-line 2013 Guidance

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 25.00

Research Provided by a Third Party

Company: DexCom, Inc.

Industry: Medical - Instruments

Record: 326

01/08/2013

Company Report

Pages: 8

Provides preliminary Q4 product revenue results, 2013 revenue guidance

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: DexCom, Inc.

Industry: Medical - Instruments

Record: 327

11/14/2012

Company Report

Pages: 9

Price: 24.95

Company: DexCom, Inc.

Industry: Medical - Instruments

Record: 328

11/02/2012

Company Report

Pages: 5

BUY ON POSITIVE NEW PRODUCT TRANSITION

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 10.00

Research Provided by a Third Party

Company: DexCom, Inc.

Industry: Medical - Instruments

Record: 329

11/02/2012

Company Report

Pages: 9

''''Tickled pink'''' - Q3 EPS less red than our estimate and new G4 color choice

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: DexCom, Inc.

Industry: Medical - Instruments

Record: 330

11/01/2012

Company Report

Pages: 4

Q3 OUTLOOK & SHARE WEAKNESS POST GEN 4 APPROVAL

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 10.00

Research Provided by a Third Party

Company: DexCom, Inc.

Industry: Medical - Instruments

Record: 331

11/01/2012

Company Report

Pages: 7

DXCM Reports In-line Q3 Sales. Focus On G4 With Early Indicators Pointing to Strong Adoption. Reiterate OUTPERFORM and $16 FV.

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 25.00

Research Provided by a Third Party

Company: DexCom, Inc.

Industry: Medical - Instruments

Record: 332

10/31/2012

Company Report

Pages: 7

Feltl CGM Project: Historical survey of 636 CGM users

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: DexCom, Inc.

Industry: Medical - Instruments

Record: 333

10/09/2012

Company Report

Pages: 5

Buy On GEN4 Platinum Fda Approval - Raising PT To $16.50

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 10.00

Research Provided by a Third Party

Company: DexCom, Inc.

Industry: Medical - Instruments

Record: 334

10/09/2012

Company Report

Pages: 8

Gen 4 approved; Q3 preliminary results - lowering EPS estimates

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: DexCom, Inc.

Industry: Medical - Instruments

Record: 335

10/08/2012

Company Report

Pages: 7

FDA clears DexCom?s G4 PLATINUM sensor; Edwards in-housing GlucoClear?

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: DexCom, Inc.

Industry: Medical - Instruments

Record: 336

10/08/2012

Company Report

Pages: 7

G4 Platinum Gets FDA Approval; Raises Bar for Competitors, In Our View

Provider: WEDBUSH SECURITIES INC.

Analyst: LAU R

Price: 25.00

Research Provided by a Third Party

Company: DexCom, Inc.

Industry: Medical - Instruments

Record: 337

08/31/2012

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of September 2, 2012

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: DexCom, Inc.

Industry: Medical - Instruments

Record: 338

08/24/2012

Company Report

Pages: 9

Price: 24.95

Company: DexCom, Inc.

Industry: Medical - Products

Record: 339

08/07/2012

Company Report

Pages: 5

Reits buy Q2 revs beat gen sensor stikk pending FDA approval, but soon

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 10.00

Research Provided by a Third Party

Company: DexCom, Inc.

Industry: Medical - Products

Record: 340

08/07/2012

Company Report

Pages: 9

DXCM DexCom reported mixed Q2 2012 results

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party